The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / NSAIDs Effective for Early Axial Spondyloarthritis

NSAIDs Effective for Early Axial Spondyloarthritis

June 10, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective, but underused, in patients with early axial spondyloarthritis, researchers from France report.

You Might Also Like
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • Subcutaneous Golimumab in Active Non-Radiographic Axial Spondyloarthritis
  • Study Examines Why Patients Exceed Recommended Doses of Ibuprofen & NSAIDs

NSAIDs are the cornerstone of treatment of axial spondyloarthritis, but there is often a trade-off between prescribing doses high enough to decrease pain and other symptoms vs. keeping the doses low enough to decrease the likelihood of adverse events.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Anna Molto from Pitie-Salpetriere Hospital in Paris and colleagues analyzed the use of NSAIDs by 627 patients who participated in DESIR, a multi-center study of patients with early inflammatory back pain of less than three years’ duration suggestive of axial spondyloarthritis.

At inclusion, 92.8% of patients had received any NSAID treatment in the prior six months. By 18 months after enrollment, this proportion had decreased to 70.2% and did not differ according to the fulfillment of the Assessment of SpondyloArthritis International Society (ASAS) criteria.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At enrollment, 15.5% of patients were in the “very low dose” NSAID category and 13% were in the “very high dose” NSAID category. By three years into the study, 45.5% of all patients were taking very low doses and 9% continued to take very high doses.

Median NSAID doses were much higher for patients with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores above 20 than for patients with BASDAI scores below 20, according to the May 26 Joint Bone Spine online report.

Mean BASDAI scores were 44.3 at inclusion, but remained at symptomatic levels (33.8) three years later.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Patients taking very low doses of NSAIDs were significantly more likely than other patients to have the absence of a good NSAID response at baseline and a history of inflammatory bowel disease.

“NSAID intake was in general very low and decreased over time, even though symptoms remained present, which suggests patients with early axial spondyloarthritis may not be receiving NSAIDs as recommended by the expert societies,” the researchers note.

“NSAID prescription in early axial spondyloarthritis is frequent, but intakes are low, and appear to correspond to an ‘on demand’ pattern,” they conclude. “Future studies focusing on the outcome of the different patterns of prescription (high vs. low, continuous vs. on demand) are needed, with an especial attention to safety and radiographic progression associated with such patterns.”

Dr. Molto was not available for comments.

The French Society of Rheumatology supported this research. The authors made no disclosures.

Filed Under: Analgesics, Drug Updates Tagged With: axial spondyloarthritis (SpA), Nonsteroidal anti-inflammatory drugs (NSAIDs), NSAIDs, Pain

You Might Also Like:
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • Subcutaneous Golimumab in Active Non-Radiographic Axial Spondyloarthritis
  • Study Examines Why Patients Exceed Recommended Doses of Ibuprofen & NSAIDs
  • A New Treatment for Axial Spondyloarthritis?

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)